Preparation and Evaluation of Novel Sugar Dendritic Gd-DTPA Complexes for MRI Contrast Agents and Phospha Sugars for Anti-Tumour Agents
Novel Sugar Dendritic Gd(III)-DTPA complexes for MRI Contrast Agents (CAs) were prepared and evaluated by in vitro and in vivo methods. The sugar dendritic MRI contrast agents had a good blood vessel pool character and drew blood vessels and liver cancers remarkably clearer and longer time enough than the clinically being used Gd(III)-DTPA complex (Magnevist). Phospha sugar derivatives or phosphorus heterocyclic derivatives provided by functional groups such as epoxide, bromide, etc., were prepared and evaluated by the MTT in vitro method. These phospha sugar derivatives showed excellent anti-proliferative effects of leukemia cell lines, e.g., K562 and U937, as well as solid cancer cells in fashions of (i) higher activity, (ii) wider spectra, and (iii) higher selectivity and specificity than Imatinib mesylate (Gleevec), which is one of the most frequently used chemotherapeutical molecular targeting anti-tumour agent.
K. Kiyofuji et al., "Preparation and Evaluation of Novel Sugar Dendritic Gd-DTPA Complexes for MRI Contrast Agents and Phospha Sugars for Anti-Tumour Agents", Advanced Materials Research, Vol. 222, pp. 217-220, 2011